CEO Executive AssistantLaunch readiness time management is the most complex multi-domain challenge a pharmaceutical CEO faces in the lifecycle of any asset. The eighteen months preceding a regulatory approval decision represent a window in which the organization must simultaneously execute a late-stage regulatory strategy, build commercial infrastructure from essentially nothing, educate the market about a new treatment option, establish payer coverage and reimbursement pathways, and maintain the pipeline activity that preserves the company’s long-term value. Every one of these workstreams is legitimate. Every one competes for CEO attention.
The CEO who tries to be deeply involved in every pre-launch workstream ends up superficially involved in all of them, providing insufficient strategic direction anywhere while consuming time that should be invested in the highest-leverage decisions. The CEO who defines her pre-launch role clearly and builds the organizational infrastructure to execute the rest creates a launch organization that operates at the necessary pace without requiring CEO involvement in execution-level decisions.
Defining the CEO’s Pre-Launch Role
Before building the pre-launch calendar, clarify the decisions in the pre-launch period that genuinely require CEO judgment versus those that should flow through functional leadership. The CEO’s unique contribution in the pre-launch period clusters into four domains.
First, commercial strategy: the fundamental decisions about market positioning, target patient population, pricing architecture, and the clinical differentiation story that will define how the product is presented to payers, prescribers, and patients. These are strategic decisions with consequences that extend years beyond launch, and they require the CEO’s business judgment and scientific understanding together.
Second, investor and external relations: maintaining investor confidence during the pre-launch period, managing the communications strategy around regulatory milestones, and building the external relationships with key opinion leaders and healthcare system executives that open commercial access at launch.
Third, organizational alignment: ensuring that the regulatory, medical affairs, commercial, and market access functions are executing a coherent strategy rather than parallel strategies that create confusion in the market. The CEO is the only executive with authority to resolve cross-functional priority conflicts that these teams generate in abundance during pre-launch.
Fourth, executive talent: the commercial leadership team assembled for a first launch, including a Chief Commercial Officer, head of market access, and heads of sales and marketing, represents one of the most consequential CEO decisions in the pre-launch period. Getting this team right is worth significant CEO time. Getting it wrong is one of the most common contributors to launch underperformance.
Everything else in the pre-launch period, including HCP education program design, sales force training content, managed care contract negotiations, and the operational details of commercial build-out, should flow through functional leadership without CEO involvement.
The Pre-Launch Calendar Architecture
Structure the eighteen-month pre-launch period into distinct phases with different CEO time profiles.
In the twelve-to-eighteen-month window, the CEO’s primary time investment is in commercial strategy finalization and commercial leadership team assembly. Pricing architecture decisions, market segmentation choices, and the medical-commercial interface that defines how clinical data is translated into commercial messaging require CEO engagement. Schedule monthly ninety-minute commercial strategy reviews in this phase, focused on the major strategic decisions rather than implementation progress.
In the six-to-twelve-month window, the CEO’s focus shifts to external relationships and organizational execution monitoring. Key opinion leader engagement, payer relationship development at the executive level, and healthcare system access conversations at major academic medical centers and integrated delivery networks require CEO presence. Build a quarterly cadence of CEO-level external relationship meetings in this phase, targeted at the ten to fifteen external stakeholders whose influence on early launch performance is most significant.
In the zero-to-six-month window, as the PDUFA date approaches, the CEO’s primary investment is in launch readiness reviews and regulatory milestone management. A monthly launch readiness assessment, reviewing commercial execution status across all workstreams against defined readiness criteria, keeps the CEO informed of risks that require decision-making intervention without embedding the CEO in operational execution.
Payer and Market Access Strategy
Payer strategy is an area where CEO time investment in the pre-launch period produces asymmetric returns. The coverage and reimbursement environment that a product launches into, including the formulary tier, prior authorization requirements, and step therapy protocols that payers impose, is substantially determined by the relationships and negotiations that occur before launch. A product that launches into favorable payer coverage across major commercial insurers and PBMs performs materially better in its first twelve months than a product that launches into adverse coverage and fights for reimbursement access retrospectively.
The CEO’s role in payer strategy is not to lead payer negotiations. That is the market access team’s function. The CEO’s role is to engage at the executive level with the largest payers at defined points in the negotiation process, signaling organizational commitment to the partnership and creating relationship capital that the market access team can leverage in negotiation.
Identify the five to eight payers whose coverage decisions most affect launch performance and schedule CEO-level meetings in the nine-to-twelve-month pre-launch window. These meetings position the organization as a committed partner, provide the opportunity for the CEO to make the clinical and economic case for favorable coverage, and create a relationship foundation that the market access team maintains through the subsequent negotiation process.
Research from McKinsey on pharmaceutical launch performance found that products with comprehensive payer engagement prior to regulatory approval achieved favorable coverage significantly faster than those that pursued payer relationships post-approval, because pre-launch engagement allowed payer decision-making processes to be completed contemporaneously with the regulatory timeline rather than sequentially after it.
Managing Regulatory Milestone Communications
In the pre-launch period, regulatory milestones create external communication events that require CEO time: investor communications around Advisory Committee meetings, regulatory responses, and the PDUFA date itself. The CEO’s communication role in these events is significant, and the preparation required for each event should be built into the pre-launch calendar explicitly.
An FDA Advisory Committee meeting is typically a multi-day CEO time investment: preparation sessions with the regulatory and medical affairs teams, investor and analyst pre-communications briefing, monitoring the meeting itself, and post-meeting communications. The PDUFA date is a launch event in its own right: the CEO should plan to be fully available for communications across investor, media, and employee audiences on and immediately after the approval date, with no competing obligations scheduled.
Build these communication events into the pre-launch calendar with protected CEO time blocks, and ensure that the investor relations and communications teams have prepared the full suite of communications materials well in advance so that the CEO’s time on the event days is spent on high-value external engagement rather than on materials preparation.
Investor day time management for pharma CEOs addresses how the investor communication demands of the pre-launch period connect to the broader investor day strategy that many pharma companies use to build investor understanding of a launch asset’s value proposition. Regulatory submissions time management for pharma CEOs covers the specific FDA submission process time management that precedes and runs parallel to the commercial launch preparation timeline.
Building Launch Infrastructure Without CEO Involvement in Execution
Commercial infrastructure for a first launch, including hiring a national sales force, building a commercial operations platform, establishing distribution and logistics, and deploying the CRM and data infrastructure that tracks commercial performance, represents enormous organizational complexity. The CEO needs to be confident that this infrastructure is being built correctly without being involved in its operational execution.
Establish a formal launch readiness program with a designated launch readiness leader, typically the Chief Commercial Officer, who is accountable for maintaining a comprehensive readiness tracker and briefing the CEO monthly on readiness status across all workstreams. Define readiness criteria for each workstream in advance: what does “ready” look like for the sales force in the ninety days before launch? For the managed care access team? For the medical affairs field team?
The CEO reviews readiness against these criteria, asks questions where confidence is insufficient, and makes decisions when workstream readiness requires CEO-level resolution. The CEO does not manage the workstreams to readiness. That is the CCO’s function.
Conclusion
Launch readiness time management for pharma CEOs is about precision in role definition during a period when the temptation to be involved in everything is at its strongest. The stakes are real: a first commercial launch is typically the most consequential value-creation event in a company’s history, and the CEO’s involvement in the critical strategic decisions is genuinely necessary.
The discipline is concentrating that involvement on the decisions that only the CEO can make, commercial strategy, commercial leadership team, external payer and stakeholder relationships, and regulatory communication, while trusting functional leaders to execute the comprehensive operational program that a successful launch requires. The CEO who achieves this discipline enters launch day with an organization that is genuinely ready, rather than an organization that relied on CEO involvement to compensate for insufficient functional leadership.